← Eichor
Condition: Suvorexant Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Suvorexant

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl
Phase 2 · 1 location(s) · Johns Hopkins University · NCT05145764Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress
Phase 4 · 4 location(s) · VA Office of Research and Development · NCT03642028Suvorexant and Alcohol
EARLY_Phase 1 · 1 location(s) · William Stoops · NCT06326684Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial
Phase 2 · 1 location(s) · Marianne Goodman · NCT06854224Trial of Suvorexant for Sleep in Children With Autism
Phase 2 · 1 location(s) · Stanford University · NCT05546554Suvorexant for Treatment of AUD and PTSD
Phase 2 · 2 location(s) · Pharmacotherapies for Alcohol and Substance Use Disorders Al · NCT06679062Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking
Phase 2 · 1 location(s) · Ohio State University · NCT07214207A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305
Phase 3 · 11 location(s) · Merck Sharp & Dohme LLC · NCT06655883Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms
Phase 1/Phase 2 · 1 location(s) · National Institute on Alcohol Abuse and Alcoholism (NIAAA) · NCT06484075
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.